|Min SIP Amount||₹100|
|NAV||₹148.02 (08 Jul 2019)|
|Fund Started||31 Dec 2012|
|Fund Size||₹2,344 Cr|
|Divi's Laboratories Ltd.||Healthcare||Equity||10.5%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||10.1%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||9.3%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||8.2%|
|Sanofi India Ltd.||Healthcare||Equity||6.7%|
|Syngene International Ltd.||Healthcare||Equity||6.5%|
|Abbott India Ltd.||Healthcare||Equity||5.6%|
Reliance Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Reliance Mutual Fund. This scheme was introduced to investors on 31 Dec 2012. Sailesh Raj Bhan is the Current Fund Manager of Reliance Pharma Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹2,344 Cr and the Latest NAV as of 08 Jul 2019 is ₹148.02.
The Reliance Pharma Fund Direct Growth is rated Moderately High risk. Minimum SIP Investment is 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.
1st Floor, Proms Complex, SBI
Colony, 1A Koramangala, 560034